Moshe Ornstein, MD, MA

Articles by Moshe Ornstein, MD, MA

Risk Factors in the Management of Advanced Renal Cell Carcinoma

ByMehmet Asim Bilen, MD,Marie Carlo, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Brian I. Rini, MD,Rana R. McKay, MD,Tom Powles, MBBS, MRCP, MD

April 19th 2022

Possible comorbidities and other risk factors in advanced renal cell carcinoma that would affect potential treatment regimens.

Choosing a Combination Treatment for Advanced Renal Cell Carcinoma

ByMehmet Asim Bilen, MD,Marie Carlo, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Brian I. Rini, MD,Rana R. McKay, MD,Tom Powles, MBBS, MRCP, MD

April 4th 2022

A look at the factors considered in choosing an appropriate combination treatment for advanced renal cell carcinoma.

Choosing a First-Line Combination Treatment Regimen for Renal Cell Carcinoma

ByMehmet Asim Bilen, MD,Marie Carlo, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Brian I. Rini, MD,Rana R. McKay, MD,Tom Powles, MBBS, MRCP, MD

April 4th 2022

Drs Rana McKay and Tom Powles debate the merits of different first-line combination treatment regimens for renal cell carcinoma.

Impressions of Data and Results from the CLEAR Trial

ByMehmet Asim Bilen, MD,Marie Carlo, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Brian I. Rini, MD,Rana R. McKay, MD,Tom Powles, MBBS, MRCP, MD

March 18th 2022

Oncologists give their initial impressions about the results of a clinical trial studying doublet combination therapies for advanced renal cell carcinoma.

Background: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

ByMehmet Asim Bilen, MD,Marie Carlo, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Brian I. Rini, MD,Rana R. McKay, MD,Tom Powles, MBBS, MRCP, MD

March 18th 2022

Robert J. Motzer, MD, presents data examined in the article, “Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.”

Moshe Ornstein, MD, MA

Articles by Moshe Ornstein, MD, MA

Risk Factors in the Management of Advanced Renal Cell Carcinoma

Choosing a Combination Treatment for Advanced Renal Cell Carcinoma

Choosing a First-Line Combination Treatment Regimen for Renal Cell Carcinoma

Impressions of Data and Results from the CLEAR Trial

Background: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Trending on CancerNetwork

Neoadjuvant Pembrolizumab/Radiotherapy Earns EU Approval in HNSCC Group

What is the Impact of the SHARON Trial on Pancreatic Cancer Research?

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC

Pembrolizumab/Belzutifan Improves DFS in ccRCC Following Nephrectomy

Career Stage and Location Found to Impact Oncology Coverage in the US